Is a Vaginectomy Enough or is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
04
2020
accepted:
17
09
2020
pubmed:
17
10
2020
medline:
18
5
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Reporting the perioperative and survival outcomes of vaginectomy with respect to a matched series of pelvic exenteration (PE) in women with isolated recurrent cervical cancer. The records of vaginal recurrent cervical cancer patients admitted at Fondazione Policlinico "Agostino Gemelli" IRCCS in Rome from January 2010 to June 2019 were retrospectively analyzed. A propensity-matched score analysis was performed by age, clinical stage, disease-free interval, and R0 resection. Postsurgical complications and survival rates were evaluated. Fifteen women underwent vaginectomy, and 30 patients were submitted to PE. No statistical differences were observed between the two groups at baseline characteristics. The vaginectomy procedures were successfully performed in all women, and no case required conversion to PE. Moreover, a higher rate of major postoperative complications after PE with respect to vaginectomy (p = 0.027) was recorded. Among them, three women required reoperation within 30 postoperative days, and four experienced two or more complications. Twenty-five (55.6%) women experienced recurrence: 8 of 25 (32.0%) in the vaginectomy group, and 17 of 25 (68%) in the PE group, with a median progression-free survival of 20 months and 13 months, respectively (p = 0.169). In total, 5 of 15 (33.3%) died of disease in the vaginectomy group and 13/30 (43.3%) in the PE group, with a median overall survival of 39 and 18 months for vaginectomy and PE, respectively (p = 0.161). The vaginectomy seems to allow for salvage treatment, such as radiotherapy and/or PE, but with a minimal impact on the quality of life in appropriately selected women with local recurrent cervical cancer.
Identifiants
pubmed: 33063258
doi: 10.1245/s10434-020-09207-w
pii: 10.1245/s10434-020-09207-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3281-3290Références
Ang C, Bryant A, Barton DP, Pomel C, Naik R. Exenterative surgery for recurrent gynaecological malignancies. Cochrane Database Syst Rev. 2014;(2):CD010449. https://doi.org/10.1002/14651858.cd010449.pub2
doi: 10.1002/14651858.cd010449.pub2
Hoeckel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies. Curr Oncol Rep. 2015;17(3):435. https://doi.org/10.1007/s11912-014-0435-8
doi: 10.1007/s11912-014-0435-8
Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer. 2014;24(1):156–64. https://doi.org/10.1097/igc.0000000000000011
doi: 10.1097/IGC.0000000000000011
pubmed: 24362721
Sardain H, Lavoue V, Redpath M, Bertheuil N, Foucher F, Levêque J. Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review. Eur J Surg Oncol. 2015;41(8):975–85. https://doi.org/10.1016/j.ejso.2015.03.235
doi: 10.1016/j.ejso.2015.03.235
pubmed: 25922209
Caceres A, Mourton SM, Bochner BH, et al. Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer 2008;18(5):1139–44. https://doi.org/10.1111/j.1525-1438.2007.01140.x
doi: 10.1111/j.1525-1438.2007.01140.x
pubmed: 18053063
Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, Podratz KC. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol. 2006;101(2):280–6. https://doi.org/10.1016/j.ygyno.2005.10.018
doi: 10.1016/j.ygyno.2005.10.018
pubmed: 16321431
Andikyan V, Khoury-Collado F, Sonoda Y, et al. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery. Gynecol Oncol. 2012;125(2):404–8. https://doi.org/10.1016/j.ygyno.2012.01.031
doi: 10.1016/j.ygyno.2012.01.031
pubmed: 22285844
Vizzielli G, Chiantera V, Tinelli G, et al. Out-of-the-box pelvic surgery including iliopsoas resection for recurrent gynecological malignancies: does that make sense? A single-institution case-series. Eur J Surg Oncol. 2017;43(4):710–6. https://doi.org/10.1016/j.ejso.2016.10.028
doi: 10.1016/j.ejso.2016.10.028
pubmed: 27890348
Vizzielli G, Naik R, Dostalek L. Laterally extended pelvic resection for gynaecological malignancies: a multicentric experience with out-of-the-box surgery. Ann Surg Oncol. 2019;26(2):523–30. https://doi.org/10.1245/s10434-018-07088-8
doi: 10.1245/s10434-018-07088-8
pubmed: 30539489
Costantini B, Vizzielli G, Fanfani F, et al. Urologic surgery in gynecologic oncology: a large single-institution experience. Eur J Surg Oncol. 2014;40(6):756–61. https://doi.org/10.1016/j.ejso.2014.01.020
doi: 10.1016/j.ejso.2014.01.020
pubmed: 24630772
Ferrandina G, Ercoli A, Fagotti A, et al. Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications. Ann Surg Oncol. 2014;21(5):1692–9. https://doi.org/10.1245/s10434-013-3471-y
doi: 10.1245/s10434-013-3471-y
pubmed: 24407316
Ferrandina G, Corrado G, Vitrano G, et al. Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer Chemother Pharmacol. 2019;83(3):431–8. https://doi.org/10.1007/s00280-018-3742-1
doi: 10.1007/s00280-018-3742-1
pubmed: 30506402
Zou W, Han Y, Zhang Y, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS ONE. 2019;14(11):e0225264. https://doi.org/10.1371/journal.pone.0225264
doi: 10.1371/journal.pone.0225264
pubmed: 31725793
pmcid: 6855659
Benedetti Panici P, Manci N, Bellati F, et al. Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence. Int J Gynecol Cancer. 2009;19(9):1625–31. https://doi.org/10.1111/igc.0b013e3181a80a0a
doi: 10.1111/IGC.0b013e3181a80a0a
pubmed: 19955949
Wijk L, Udumyan R, Pache B, et al. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. Am J Obstet Gynecol. 2019;221(3):237.e1–237.e11. https://doi.org/10.1016/j.ajog.2019.04.028 .
doi: 10.1016/j.ajog.2019.04.028
Strong VE, Selby LV, Sovel M, et al. Development and assessment of memorial sloan kettering cancer center’s surgical secondary events grading system. Ann Surg Oncol. 2015;22(4):1061–7. https://doi.org/10.1245/s10434-014-4141-4
doi: 10.1245/s10434-014-4141-4
pubmed: 25319579
Cibula D. Pelvic exenteration for gynecological cancers. In: Ramirez PT, Frumovitz M, Abu-Rustum N (eds) Principles of gynecologic oncology surgery. Elsevier, Philadelphia, 2018.
Vizzielli G, Perrone E, Pizzacalla S, Scambia G, Ercoli A. Laparoscopic pelvic exenteration with radical vaginectomy using 3-dimensional vision and multifunction instrument. Int J Gynecol Cancer. 2018;28(9):1805–6. https://doi.org/10.1097/igc.0000000000001370
doi: 10.1097/IGC.0000000000001370
pubmed: 30358707
Vizzielli G, Fanfani F, Chiantera V, et al. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? Anticancer Res. 2015;35:3027–3032.
pubmed: 25964591
Bizzarri N, Chiantera V, Ercoli A, et al. Minimally invasive pelvic exenteration for gynecologic malignancies: a multi-institutional case series and review of the literature. J Minim Invasive Gynecol. 2019;26(7):1316–26. https://doi.org/10.1016/j.jmig.2018.12.019
doi: 10.1016/j.jmig.2018.12.019
pubmed: 30611973
Nakasone T, Taira Y, Shimoji Y, et al. Hysterectomy for recurrent/residual cervical cancer following definitive radiotherapy. In Vivo. 2020;34(4):2173–7. https://doi.org/10.21873/invivo.12026 .
doi: 10.21873/invivo.12026
Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017; 390:1654–63. https://doi.org/10.1016/s0140-6736(17)31607-0
doi: 10.1016/S0140-6736(17)31607-0
pubmed: 28756902
pmcid: 5714293
Dessole M, Petrillo M, Lucidi A, et al. Quality of life in women after pelvic exenteration for gynecological malignancies: a multicentric study. Int J Gynecol Cancer. 2018;28(2):267–73. https://doi.org/10.1097/igc.0000000000000612
doi: 10.1097/IGC.0000000000000612
pubmed: 26807639
Federico A, Gallotta V, Foschi N, Costantini B, Conte C, Pinto F, Ercoli A, Ferrandina G, Dal Moro F, Bassi P, Zattoni F, Scambia G, Vizzielli G. Surgical outcomes of segmental ureteral resection with ureteroneocystostomy after major gynecologic surgery. Eur J Surg Oncol. 2020 (In press). https://doi.org/10.1016/j.ejso.2020.03.216
doi: 10.1016/j.ejso.2020.03.216
pubmed: 32278519
Chiantera V, Rossi M, De Iaco P, et al. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients. Int J Gynecol Cancer. 2014;24(5):916–22. https://doi.org/10.1097/igc.0b013e3182a80aec
doi: 10.1097/IGC.0b013e3182a80aec
pubmed: 24442006